Diagnocure, Inc. (DGCRF)
Diagnocure, Inc. operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Quebec, QC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $21,520. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -698.6%. Its beta of -15.95 implies it has historically moved less than the broad market.
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.
Diagnocure, Inc. is most often compared with the following Healthcare names: